chain of custody comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Adrenomedullin (AM) Angiopoietin (Ang) Autocrine motility factor Bone morphogenetic proteins (BMPs) Ciliary neurotrophic factor family Colony-stimulating factors Epidermal growth factor (EGF) Ephrin Fibroblast growth factor (FGF) Foetal Bovine Somatotrophin (FBS) GDNF family of ligands Growth differentiation factor-9 (GDF9) Hepatocyte growth factor (HGF) Hepatoma-derived growth factor (HDGF) Insulin Insulin-like growth factors Interleukins Keratinocyte growth factor (KGF) Migration-stimulating factor (MSF) Macrophage-stimulating protein (MSP), also known as hepatocyte growth factor-like protein (HGFLP) Myostatin (GDF-8) Neuregulins Neurotrophins Placental growth factor (PGF) Platelet-derived growth factor (PDGF) Transforming growth factors Vascular endothelial growth factor (VEGF)
== External links == Video of the Daisy ad, from the PBS website A Historical Look at Campaign Commercials The Emergence of the Maimed Hero Spy vs Spy Gallery Missile Command at the Killer List of Videogames
Intracellular ice can be much more damaging than extracellular ice. For red blood cells, the optimum cooling rate is very rapid (nearly 100 °C per second), whereas for stem cells the optimum cooling rate is very slow (1 °C per minute). Cryoprotectants, such as dimethyl sulfoxide and glycerol, are used to protect cells from freezing. A variety of cell types are protected by 10% dimethyl sulfoxide. Cryobiologists attempt to optimize cryoprotectant concentration (minimizing both ice formation and toxicity) and cooling rate. Cells may be cooled at an optimum rate to a temperature between −30 and −40 °C before being plunged into liquid nitrogen. Slow cooling methods rely on the fact that cells contain few nucleating agents, but contain naturally occurring vitrifying substances that can prevent ice formation in cells that have been moderately dehydrated. Some cryobiologists are seeking mixtures of cryoprotectants for full vitrification (zero ice formation) in preservation of cells, tissues, and organs. Vitrification methods pose a challenge in the requirement to search for cryoprotectant mixtures that can minimize toxicity.
1953 - Li was the first to isolate and extract ACTH. 1964 - Li and his research team discovered and isolated lipotropin, and its structure was defined in 1965. 1975 - Li discovered β-endorphin when trying to find β-lipotropin in camel brain. The team isolated human β-endorphin in 1976 and synthesized it to study its biological activity after they defined the structure of β-endorphin. The second group includes follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH).
Sources: en.wikipedia.org
HMF can be found in low amounts in honey, fruit-juices and UHT-milk. Here, as well as in vinegars, jams, alcoholic products or biscuits, HMF can be used as an indicator for excess heat-treatment. For instance, fresh honey contains less than 15 mg/kg—depending on pH-value and temperature and age, and the codex alimentarius standard requires that honey have less than 40 mg/kg HMF to guarantee that the honey has not undergone heating during processing, except for tropical honeys which must be below 80 mg/kg. Higher quantities of HMF are found naturally in coffee and dried fruit. Several types of roasted coffee contained between 300 – 2900 mg/kg HMF. Dried plums were found to contain up to 2200 mg/kg HMF. In dark beer 13.3 mg/kg were found, bakery-products contained between 4.1 – 151 mg/kg HMF. It can be found in glucose syrup. HMF can form in high-fructose corn syrup (HFCS), levels around 20 mg/kg HMF were found, increasing during storage or heating. This is a problem for American beekeepers because they use HFCS as a source of sugar when there are not enough nectar sources to feed honeybees, and HMF is toxic to them. Adding bases such as soda ash or potash to neutralize the HFCS slows the formation of HMF. Depending on production-technology and storage, levels in food vary considerably. To evaluate the contribution of a food to HMF intake, its consumption-pattern has to be considered. Coffee is the food that has a very high relevance in terms of levels of HMF and quantities consumed. HMF is a natural component in heated food but usually present in low concentrations.
agonist Any ligand (especially a drug or hormone) that in binding to or interacting with a receptor protein causes a conformational change that converts the receptor into an active form, thereby initiating a biological response. In contrast, an inverse agonist has the opposite effect on the receptor, inactivating or disabling it, while an antagonist competes with or directly blocks the agonist, preventing it from activating the receptor.
==== ssDNA vs. dsDNA ==== Most DNA molecules are actually two polymer strands, bound together in a helical fashion by noncovalent bonds; this double-stranded (dsDNA) structure is maintained largely by the intrastrand base stacking interactions, which are strongest for G,C stacks. The two strands can come apart—a process known as melting—to form two single-stranded DNA (ssDNA) molecules. Melting occurs at high temperatures, low salt and high pH (low pH also melts DNA, but since DNA is unstable due to acid depurination, low pH is rarely used). The stability of the dsDNA form depends not only on the GC-content (% G,C basepairs) but also on sequence (since stacking is sequence specific) and also length (longer molecules are more stable). The stability can be measured in various ways; a common way is the melting temperature (also called Tm value), which is the temperature at which 50% of the double-strand molecules are converted to single-strand molecules; melting temperature is dependent on ionic strength and the concentration of DNA. As a result, it is both the percentage of GC base pairs and the overall length of a DNA double helix that determines the strength of the association between the two strands of DNA. Long DNA helices with a high GC-content have more strongly interacting strands, while short helices with high AT content have more weakly interacting strands. In biology, parts of the DNA double helix that need to separate easily, such as the TATAAT Pribnow box in some promoters, tend to have a high AT content, making the strands easier to pull apart.
Many Irish nationalists sympathised with the Boers as oppressed by British imperialism, much like they viewed themselves. Irish miners already in the Transvaal at the start of the war formed the nucleus of two Irish commandos. The Second Irish Brigade was headed by an Australian of Irish parents, Colonel Arthur Lynch. Groups of Irish volunteers went to fight with the Boers—despite the fact that there were many Irish troops fighting in the British army, including the Royal Dublin Fusiliers. In Britain, the "Pro-Boer" campaign expanded, with writers often idealising the Boer society. The war highlighted the dangers of Britain's policy of non-alignment and deepened her isolation. The 1900 UK general election, also known as the "Khaki election", was called by the Prime Minister, Lord Salisbury, on the back of British victories. There was much enthusiasm for the war at this point, resulting in a victory for the Conservative government. However, support waned as it became apparent the war would not be easy and it dragged on, partially contributing to the Conservatives' spectacular defeat in 1906. There was outrage at scorched earth tactics and conditions in the concentration camps. It became apparent there were serious problems with public health in Britain as up to 40% of recruits in Britain were unfit for conscription, and suffered from medical problems such as rickets and other poverty-related illnesses. This came at a time of increasing concern for the poor in Britain. 22,000 Empire troops were killed.
BMP: The What and the Who BMPedia - the Bone Morphogenetic Protein Wiki Bone+Morphogenetic+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Chen D, Zhao M, Mundy GR (Dec 2004). "Bone morphogenetic proteins". Growth Factors (Chur, Switzerland). 22 (4): 233–241. doi:10.1080/08977190412331279890. PMID 15621726. S2CID 22932278. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC (Aug 2003). "Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)". The Journal of Bone and Joint Surgery. American Volume. 85-A (8): 1544–52. doi:10.2106/00004623-200308000-00017. PMID 12925636. link[link removed]
Sources: en.wikipedia.org
=== Microscopic features === Psilocybe baeocystis spores are dark purplish brown in deposit, oblong in face view or asymmetric ellipsoid (mango form) in side view, and are (8.5) 9.5–13.7(17) x (5) 5.5–6.6(7.1) μm. The basidia are 4-spored, and pleurocystidia are absent. The cheilocystidia are 20–30(40) x 4.5–6(9) μm and fusiod with a narrow neck. This species closely resembles subtropical Psilocybe aztecorum and Psilocybe quebecensis, which also have caps that bleach in color to white when dry.
=== Tennessee === On March 21, 2024, the State of Tennessee enacted legislation called the ELVIS Act, aimed specifically at audio deepfakes, and voice cloning. This legislation was the first enacted legislation in the nation aimed at regulating AI simulation of image, voice and likeness. The bill passed unanimously in the Tennessee House of Representatives and Senate. This legislation's success was hoped by its supporters to inspire similar actions in other states, contributing to a unified approach to copyright and privacy in the digital age, and to reinforce the importance of safeguarding artists' rights against unauthorized use of their voices and likenesses.
Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, buccal, ocular, nasal, rectal, transdermal, subcutaneous, or sublingual administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of exposure to a drug (AUC) through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered. In pharmacology, in order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. The formula for calculating the absolute bioavailability, F, of a drug administered orally (po) is given below (where D is dose administered).
=== Independent investigations === In June 2021, the NIH announced that a set of sequence data had been removed from the Sequence Read Archive (SRA) in June 2020. The removal was performed according to standard practice at the request of the investigators who owned the rights to the sequences, with the investigators' rationale that the sequences would be submitted to another database. The investigators subsequently published a paper in an academic journal the same month they were removed from the NIH database which described the sequences in detail and discussed their evolutionary relationship to other sequences, but did not include the raw data. Virologist David Robertson said that it was difficult to conclude it was a cover-up rather than the more likely explanation: a mundane deletion of data without malfeasance. The missing genetic sequence data was restored in a correction published 29 July 2021 after it was stated to be a copy-edit error. In September 2024, a study published in Cell found genetic evidence that COVID-19 may have originated from the illegal trade of infected raccoon dogs in Wuhan, China, supporting the zoonotic transmission scenario. Swabs taken from the Huanan Seafood Wholesale Market in January 2020, which tested positive for coronavirus, contained large amounts of genetic material from raccoon dogs.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.